Palifermin (Kepivance) for myelotoxic-therapy-related mucositis

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1207, 2005, Pages 36-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; OPIATE DERIVATIVE; PALIFERMIN; PLACEBO;

BOLUS INJECTION; BONE MARROW TOXICITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MECHANISM; DRUG TOLERABILITY; DYSESTHESIA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RISK; MUCOSA INFLAMMATION; NONHUMAN; PARENTERAL NUTRITION; PRURITUS; SHORT SURVEY; TASTE DISORDER; TONGUE DISEASE;

EID: 85047657813     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. ST Sonis and FG Fey. Oral complications of cancer therapy. Oncology 2002; 16:680.
2. AM Rose-Ped, et al. Computations of radiation therapy for head and neck cancers. Cancer Nurs 2002; 25:461.
3. ST Sonis et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19:2201.
4. R Spielberger et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590.